Arno Therapeutics’ AR-13 Shows Promise as Potential New Cystic Fibrosis Therapeutic Option for Serious Bacterial Infections

Flemington, New Jersey based clinical stage biopharmaceutical company Arno Therapeutics, Inc. has announced data from a preclinical study demonstrating that its drug candidate AR-13, an analogue of Arno’s AR-12 infectious disease compound portfolio, shows promise as a potential new therapeutic option for patients with cystic fibrosis (CF) who are…